Jim Cramer: Buy ARM Holdings, Sell Baidu, and 2 More Stock Picks

Jim Cramer made the following calls on September 17th, 2013. What do you think about his picks?

ARM Holdings plc (NASDAQ:ARMH): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on January 12, 2012. The stock’s 52-week high is $50.56, and its 52-week low is $27.12. The stock seems to be favorable in the short term because of its moving averages, and Cramer remains optimistic about ARM.

armh-20130918

Baidu, Inc. (NASDAQ:BIDU): Jim Cramer ranked this stock a Sell. Cramer previously ranked this stock a Sell on March 27, 2013. The stock’s 52-week high is $148.25, and its 52-week low is $82.98. Cramer was not a fan of Baidu, noting that investing in a company headquartered in China posed a significant risk at the current point in time due to political and economic forces at work in the country. Baidu’s stock price increased by approximately 50 percent this July, but the fantastic gains have yet to continue since then.

bidu-20130918

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA): Jim Cramer ranked this stock a Sell. Cramer previously ranked this stock a Sell on August 29, 2013. The stock’s 52-week high is $11.00, and its 52-week low is $5.72. Cramer was bearish about Arena, a company which recently announced that it would be presenting data about its BELVIQ drug, which promotes weight loss by chemically creating the feeling of satiety, at a diabetes conference later this month.

arna-20130918

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on August 27, 2013. The stock’s 52-week high is $76.34, and its 52-week low is $36.28. Cramer sat down with Jean-Jacques Bienaime, the CEO of BioMarin, to talk about the company’s recent success. Bienaime claimed that, in the pharmaceutical industry, it is not so much about sales numbers and more about improving the quality of life of patients, saying that, though BioMarin’s products are only sold to a handful of customers, they genuinely improve their lives. Bienaime also hinted that BioMarin’s next drug, which could stand to double their revenue, is currently in Phase III testing.

bmrn-20130918

Don’t Miss: Is the Microsoft Acquisition Delaying Nokia’s Phablet Launch?